PBM — Psyence Biomedical Cashflow Statement
0.000.00%
- $0.23m
- -$0.50m
Annual cashflow statement for Psyence Biomedical, fiscal year end - March 31st, USD millions except per share, conversion factor applied.
2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | 20-F |
Standards: | IFRS | IFRS | IFRS | IFRS |
Status: | fx Final | Final | Final | Final |
Net Income/Starting Line | -1.85 | -3.21 | -51.2 | 1.01 |
Depreciation | ||||
Non-Cash Items | 0.331 | 0.137 | 49.4 | -4.36 |
Unusual Items | ||||
Other Non-Cash Items | ||||
Changes in Working Capital | 0.129 | 1.48 | -1.17 | -0.386 |
Change in Accounts Receivable | ||||
Change in Prepaid Expenses | ||||
Change in Payable / Accrued Expenses | ||||
Other Operating Cash Flow | ||||
Cash from Operating Activities | -1.39 | -1.59 | -2.95 | -3.73 |
Capital Expenditures | — | 0 | -0.006 | -0.01 |
Purchase of Fixed Assets | ||||
Other Investing Cash Flow Items | -0.032 | — | — | -0.006 |
Other Investing Cash Flow | ||||
Cash from Investing Activities | -0.032 | 0 | -0.006 | -0.016 |
Financing Cash Flow Items | -1.62 | 1.17 | 0 | 8.15 |
Other Financing Cash Flow | ||||
Net Issuance / Retirement of Debt | ||||
Cash from Financing Activities | -1.62 | 1.17 | 2.35 | 9.15 |
Beginning Cash Balance | ||||
Ending Cash Balance | ||||
Net Change in Cash | -3.04 | -0.419 | -0.601 | 5.4 |